title: Comparison of cytomegalovirus (CMV) antigenemia and CMV in bronchoalveolar lavage fluid for diagnosis of CMV pulmonary infection after bone marrow transplantation.
abstract: A comparative cytomegalovirus (CMV) diagnostic study was carried out on 30 bone marrow transplant patients. Forty-three bronchoalveolar lavage fluid (BALF) samples from these patients were examined for CMV by viral culture, polymerase chain reaction (PCR), shell vial and cytology. In parallel, peripheral blood samples were subjected to CMV antigenemia assay. CMV was detected in 12 (27.9%) of the 43 BALF samples (10 samples in viral culture, 10 samples in PCR, eight samples in shell vial and three samples in cytology). The CMV antigenemia assay yielded a positive result for six samples. The rates of agreement between results of the CMV antigenemia assay and results of each of the BALF tests were as follows: 81.4% with viral culture, 76.7% with PCR, 86.0% with shell vial, and 88.4% with cytology. Although the sensitivity of the CMV antigenemia assay was inferior to the sensitive tests of BALF samples, statistically significant correlations were demonstrated between the CMV antigenemia assay, viral culture, shell vial and cytology. Although the CMV antigenemia assay was shown to be useful for detection of CMV, it may be necessary to confirm not only the sensitivity but also the specificity of this method for prevention of CMV disease after BMT.
authors.affiliation: Bone Marrow Transplantation Team, Metropolitan Komagome General Hospital, Bunkyo-ku, Tokyo, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Sakamaki
authors.forename: K
authors.initials: K
authors.lastname: Yuasa
authors.forename: H
authors.initials: H
authors.lastname: Goto
authors.forename: S
authors.initials: S
authors.lastname: Tanikawa
authors.forename: H
authors.initials: H
authors.lastname: Akiyama
authors.forename: Y
authors.initials: Y
authors.lastname: Onozawa
authors.forename: R
authors.initials: R
authors.lastname: Okamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Maeda
authors.forename: T
authors.initials: T
authors.lastname: Sasaki
authors.forename: H
authors.initials: H
authors.lastname: Kaku
authors.forename: S
authors.initials: S
authors.lastname: Tsuzuki
authors.forename: S
authors.initials: S
authors.lastname: Takamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Mochida
authors.forename: T
authors.initials: T
authors.lastname: Minematsu
authors.forename: Y
authors.initials: Y
authors.lastname: Minamishima
mesh_terms: D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000150:complications / Q000628:therapy; D000956:Antigens, Viral / Q000097:blood*; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D001992:Bronchoalveolar Lavage Fluid / Q000821:virology*; D003587:Cytomegalovirus; D003586:Cytomegalovirus Infections / Q000175:diagnosis*; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000628:therapy; D011024:Pneumonia, Viral / Q000175:diagnosis*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000628:therapy
chemical_list: D000956:Antigens, Viral